Aurinia Pharmaceuticals shares gained nearly 4% pre-market after beating Q4 earnings and revenue estimates, reporting $1.53 EPS on $77.1 million sales. However, the 2026 revenue guidance of $315-325 million fell short of Wall Street expectations. Despite the outlook miss, retail sentiment remains bullish.